CoChat

Glucagon-like peptide 1 levels predict cardiovascular risk in patients with acute myocardial infarction

Kahles, Florian, Rückbeil, Marcia V, Mertens, Robert W, Foldenauer, Ann C, Arrivas, Maria C, Moellmann, Julia, Lebherz, Corinna, Biener, Moritz, Giannitsis, Evangelos, Katus, Hugo A, Marx, Nikolaus, Lehrke, Michael · 2020 · European Heart Journal
Cited by 44

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Aims: Glucagon-like peptide 1 (GLP-1) is a gut incretin hormone inducing post-prandial insulin secretion. Glucagon-like peptide 1 levels were recently found to be increased in patients with acute myocardial infarction. Glucagon-like peptide 1 receptor agonists improve cardiovascular outcomes in patients with diabetes. The aim of this study was to assess the predictive capacity of GLP-1 serum levels for cardiovascular outcome in patients with myocardial infarction. Methods and results: In 918 patients presenting with myocardial infarction [321 ST-segment elevation myocardial infarction and 597 non-ST-segment elevation myocardial infarction (NSTEMI)] total GLP-1, N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels and the Global Registry of Acute Coronary Events (GRACE) score were assessed at time of hospital admission. The primary composite outcome of the study was the first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. Kaplan–Meier survival plots and univariable Cox regression analyses found GLP-1 to be associated with adverse outcome [hazard ratio (HR) of logarithmized GLP-1 values: 6.29, 95% confidence interval (CI): 2.67–14.81; P < 0.0001]. After further adjustment for age, sex, family history of cardiovascular disease, smoking, diabetes, hypertension, hypercholesterinaemia, glomerular filtration rate (GFR) CKD-EPI, hs-CRP, hs-Troponin T, and NT-proBNP levels the HR remained significant at 10.98 (95% CI: 2.63–45.90; P = 0.0010). Time-dependent receiver operating characteristic curve analyses illustrated that GLP-1 levels are a strong indicator for early events. For events up to 30 days after admission, GLP-1 proved to be superior to other biomarkers including hs-Troponin T, GFR CKD-EPI, hs-CRP, and NT-proBNP. Adjustment of the GRACE risk estimate by addition of GLP-1 increased the area under the receiver operating characteristic curve over time in NSTEMI patients. Conclusion: In patients hospitalized for myocardial infarction, GLP-1 levels are associated with cardiovascular events.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehz728

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 25

  1. Roffi, 2016, 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-Segment Elevation of the European Society of Cardiology (ESC), Eur Heart J, 37, 267, 10.1093/eurheartj/ehv320 · DOI · Paper page
  2. Antman, 2000, The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making, JAMA, 284, 835, 10.1001/jama.284.7.835 · DOI · Paper page
  3. Fox, 2006, Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE), BMJ, 333, 1091., 10.1136/bmj.38985.646481.55 · DOI · Paper page
  4. Lehrke, 2012, New antidiabetic therapies: innovative strategies for an old problem, Curr Opin Lipidol, 23, 569, 10.1097/MOL.0b013e328359b19f · DOI
  5. Gerstein, 2019, Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial, Lancet, 394, 121, 10.1016/S0140-6736(19)31149-3 · DOI · Paper page
  6. Diebold, 2018, Myocardial infarction is sufficient to increase GLP-1 secretion, leading to improved left ventricular contractility and mitochondrial respiratory capacity, Diabetes Obes Metab, 20, 2911, 10.1111/dom.13472 · DOI
  7. 2017, R: A Language and Environment for Statistical Computing
  8. Blanche, 2013, Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks, Stat Med, 32, 5381, 10.1002/sim.5958 · DOI · Paper page
  9. Lonborg, 2012, Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia, Circ Cardiovasc Interv, 5, 288, 10.1161/CIRCINTERVENTIONS.112.968388 · DOI · Paper page
  10. Lonborg, 2012, Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction, Eur Heart J, 33, 1491, 10.1093/eurheartj/ehr309 · DOI · Paper page
  11. Woo, 2013, Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study, Arterioscler Thromb Vasc Biol, 33, 2252, 10.1161/ATVBAHA.113.301586 · DOI · Paper page
  12. Dutta, 2012, Myocardial infarction accelerates atherosclerosis, Nature, 487, 325, 10.1038/nature11260 · DOI · Paper page
  13. Hilgendorf, 2014, Ly-6Chigh monocytes depend on Nr4a1 to balance both inflammatory and reparative phases in the infarcted myocardium, Circ Res, 114, 1611, 10.1161/CIRCRESAHA.114.303204 · DOI · Paper page
  14. Ellingsgaard, 2011, Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells, Nat Med, 17, 1481, 10.1038/nm.2513 · DOI · Paper page
  15. Kahles, 2014, GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering, Diabetes, 63, 3221, 10.2337/db14-0100 · DOI · Paper page
  16. Lebherz, 2016, Interleukin-6 predicts inflammation-induced increase of Glucagon-like peptide-1 in humans in response to cardiac surgery with association to parameters of glucose metabolism, Cardiovasc Diabetol, 15, 21., 10.1186/s12933-016-0330-8 · DOI · Paper page
  17. Cavusoglu, 2011, Plasma interleukin-10 levels and adverse outcomes in acute coronary syndrome, Am J Med, 124, 724, 10.1016/j.amjmed.2011.02.040 · DOI
  18. Murray, 2005, The primary mechanism of the IL-10-regulated antiinflammatory response is to selectively inhibit transcription, Proc Natl Acad Sci U S A, 102, 8686, 10.1073/pnas.0500419102 · DOI · Paper page
  19. Vila, 2008, Plasma NT-proBNP increases in response to LPS administration in healthy men, J Appl Physiol (1985), 105, 1741, 10.1152/japplphysiol.90442.2008 · DOI
  20. Omland, 1996, Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide, Circulation, 93, 1963, 10.1161/01.CIR.93.11.1963 · DOI · Paper page
  21. Burley, 2007, B-type natriuretic peptide at early reperfusion limits infarct size in the rat isolated heart, Basic Res Cardiol, 102, 529, 10.1007/s00395-007-0672-1 · DOI
  22. Klingenberg, 2018, Improved risk stratification of patients with acute coronary syndromes using a combination of hsTnT, NT-proBNP and hsCRP with the GRACE score, Eur Heart J Acute Cardiovasc Care, 7, 129, 10.1177/2048872616684678 · DOI
  23. Thomas, 2017, Novel risk markers and risk assessments for cardiovascular disease, Circ Res, 120, 133, 10.1161/CIRCRESAHA.116.309955 · DOI
  24. Chattopadhyay, 2018, Adjustment of the GRACE score by 2-hour post-load glucose improves prediction of long-term major adverse cardiac events in acute coronary syndrome in patients without known diabetes, Eur Heart J, 39, 2740, 10.1093/eurheartj/ehy233 · DOI
  25. Gyberg, 2015, Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: a report from EUROASPIRE IV—a survey from the European Society of Cardiology, Eur Heart J, 36, 1171, 10.1093/eurheartj/ehv008 · DOI · Paper page

Cited by

See all 44

Metadata

Authors
Kahles, F., Rückbeil, M. V., Mertens, R. W., Foldenauer, A. C., Arrivas, M. C., Moellmann, J., Lebherz, C., Biener, M., Giannitsis, E., Katus, H. A., Marx, N., & Lehrke, M.
Venue
European Heart Journal
Published
2019-10-16
Volume
41
Issue
7
Pages
882-889
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2980320630
Cited by
44
References
9
FWCI
3.59
Type
journal article
Language
en
Open access
closed
Funders
  • Else Kröner-Fresenius Foundation and the German Society for Cardiology
  • Deutsche Forschungsgemeinschaft (SFB TRR 219 M-03, SFB TRR 219 M-03 and M-05)
  • Marga und Walter Boll-Stiftung

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon-like peptide 1 levels predict cardiovascular risk in patients with acute myocardial infarction. https://app.cochat.ai/papers/10.1093/eurheartj/ehz728
The paper
Kahles, F., Rückbeil, M. V., Mertens, R. W., Foldenauer, A. C., Arrivas, M. C., Moellmann, J., Lebherz, C., Biener, M., Giannitsis, E., Katus, H. A., Marx, N., & Lehrke, M. (2020). Glucagon-like peptide 1 levels predict cardiovascular risk in patients with acute myocardial infarction. European Heart Journal. https://doi.org/10.1093/eurheartj/ehz728

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.